These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6732543)

  • 21. Soluble CD23 as an effector of immune dysregulation in chronic uremia and dialysis.
    Descamps-Latscha B; Herbelin A; Nguyen AT; de Groote D; Chauveau P; Verger C; Jungers P; Zingraff J
    Kidney Int; 1993 Apr; 43(4):878-84. PubMed ID: 8479124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contrasting effect of hemodialysis and peritoneal dialysis on the inhibition of in vitro calcification by uremic serum.
    Oreopoulos DG; Pitel S; Husdan H; de Veber GA; Rapoport A
    Can Med Assoc J; 1974 Jan; 110(1):43-7. PubMed ID: 4809445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure.
    McGonigle RJ; Husserl F; Wallin JD; Fisher JW
    Kidney Int; 1984 Feb; 25(2):430-6. PubMed ID: 6727138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of blood transfusion on cellular immunity.
    Giacchino F; Coppo R; Giachino G; Belardi P; Pellerey M; Piccoli G
    Immunol Lett; 1982 Nov; 5(5):253-7. PubMed ID: 6761266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell mediated immune reactivity in hemodialysis patients.
    Plavljanic D; Molnar V; Vitale B; Benkovic B
    Minerva Nefrol; 1979; 26(2):169-72. PubMed ID: 471343
    [No Abstract]   [Full Text] [Related]  

  • 26. The immune status of the uremic patient: hemodialysis vs CAPD.
    Schollmeyer P; Bozkurt F
    Clin Nephrol; 1988; 30 Suppl 1():S37-40. PubMed ID: 3052959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitors of lymphocyte activity in peritoneal fluid of continuous ambulatory peritoneal dialysis (CAPD).
    Giangrande A; Cantù P; De Francesco D; Limido A
    Int J Artif Organs; 1984 Mar; 7(2):63-6. PubMed ID: 6735497
    [No Abstract]   [Full Text] [Related]  

  • 28. [The Veneto Region's Registry of Dialysis and Transplantation: 2006-2007 report].
    Antonucci F; Camerin E; Feriani M; Nordio M; Piccoli A; Rossi B; Tessitore N
    G Ital Nefrol; 2009; 26 Suppl 48():S5-56. PubMed ID: 19927265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uremia as a state of immune deficiency.
    Birkeland SA
    Scand J Immunol; 1976; 5(1-2):107-15. PubMed ID: 131369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative overview of the nutritional status of patients on hemodialysis and peritoneal dialysis].
    VujićD ; Petrović M; Radovanović Lj; Popović J
    Srp Arh Celok Lek; 1991; 119(7-8):194-7. PubMed ID: 1792576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Assessment of nutrition in dialysis patients and chronic uremic patients].
    Liu H; Duan X; Li G
    Zhonghua Nei Ke Za Zhi; 1997 Nov; 36(11):727-30. PubMed ID: 10451942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative analysis of immunophenotypic abnormalities in cellular immunity of uremic patients undergoing either hemodialysis or continuous ambulatory peritoneal dialysis.
    Griveas I; Visvardis G; Fleva A; Papadopoulou D; Mitsopoulos E; Kyriklidou P; Manou E; Ginikopoulou E; Meimaridou D; Paulitou A; Sakellariou G
    Ren Fail; 2005; 27(3):279-82. PubMed ID: 15957543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of uremic middle molecules on in vitro stimulated lymphocytes and interleukin-2 production.
    Severini G; Diana L; Di Giovannandrea R; Sagliaschi G
    ASAIO J; 1996; 42(1):64-7. PubMed ID: 8808461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphocyte proliferation in uremic patients: correlation with zinc status.
    Shu KH; Lu YS; Chen CH; Chen DC; Lee SH; Lian JD
    J Formos Med Assoc; 1993 Nov; 92(11):1017-20. PubMed ID: 7910061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of interferon response in lymphocytes from patients with uremia.
    Sanders CV; Luby JP; Sanford JP; Hull AR
    J Lab Clin Med; 1971 May; 77(5):768-76. PubMed ID: 5557663
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of levamisole on E rosette inhibition by serum of malnourished children.
    Salimonu LS
    Biomed Pharmacother; 1983; 37(6):276-80. PubMed ID: 6200157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of allogeneic lymphocyte E-rosettes induced by sera from newly diagnosed type I diabetics.
    Pozzilli P; Di Mario U; Javicoli M; Menzinger G; Andreani D
    Acta Endocrinol (Copenh); 1980 Jan; 93(1):49-53. PubMed ID: 6986737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autopsy findings in diabetic nephropathy patients under dialysis, collected from the annuals of pathological autopsy cases in Japan.
    Hida M; Saitoh H; Satoh T
    Tokai J Exp Clin Med; 1984 Dec; 9(5-6):357-62. PubMed ID: 6545481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro characterization of immunological responsiveness of uremic patients.
    Kunori T; Fehrman I; Ringdén O; Möller E
    Nephron; 1980; 26(5):234-9. PubMed ID: 6448353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phagocytosis and neutrophil bactericidal capacity in patients with uremia.
    Wierusz-Wysocka B; Wysocki H; Michta G; Wykretowicz A; Czarnecki R; Baczyk K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(5):589-94. PubMed ID: 6083931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.